*/
Lev Gerlovin, Ezra Josephson | Life Sciences
Let’s say interchangeability is a viable regulatory option for manufacturers of biosimilars. Would it always make sense to seek an interchangeability designation from a strategic perspective? Because of the diversity and complexity of product and manufacturer characteristics, there may not be a single optimal strategy, but rather a continuum. Click below to read the article.
Ending the HIV epidemic: Ensuring equitable access to innovative HIV treatment and care
While advances in prevention, testing, and treatment have transformed outcomes for many people living with or at risk of HIV, significant inequities continue...